Abstract
MicroRNAs have emerged as key players of gene regulation during development and disease states like cancer and cardiovascular diseases. Pulmonary arterial hypertension (PAH), a vascular disease characterized by pulmonary resistance and vessel occlusion, is not spared by microRNA implication. This is not surprising since PAH shares common aberrantly activated pathways with cancers that lead to proliferation and survival of pulmonary arterial smooth muscle cells, among others, within the artery wall and narrowing the lumen. Recent studies demonstrated the role of miR-204 and miR- 206 in pulmonary artery smooth muscle cell (PASMC) proliferation. Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. During the last couple of years, the number of studies on the role of microRNA in PAH has broadened, defining it clearly as a HOT TOPIC. This current review presents an overview of the most recent knowledge as well as future possibilities. The use of microRNA therapies is still uncertain and poorly applied in the clinical setting yet. It is still critical to increase the knowledge and the translational potential of this HOT TOPIC to make it become a HOPE TOPIC.
Keywords: Biomarker, microRNA, molecular biology, pulmonary arterial hypertension, remodeling, therapeutic target.
Current Vascular Pharmacology
Title:Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension
Volume: 13 Issue: 3
Author(s): Jolyane Meloche, Roxane Paulin, Steeve Provencher and Sebastien Bonnet
Affiliation:
Keywords: Biomarker, microRNA, molecular biology, pulmonary arterial hypertension, remodeling, therapeutic target.
Abstract: MicroRNAs have emerged as key players of gene regulation during development and disease states like cancer and cardiovascular diseases. Pulmonary arterial hypertension (PAH), a vascular disease characterized by pulmonary resistance and vessel occlusion, is not spared by microRNA implication. This is not surprising since PAH shares common aberrantly activated pathways with cancers that lead to proliferation and survival of pulmonary arterial smooth muscle cells, among others, within the artery wall and narrowing the lumen. Recent studies demonstrated the role of miR-204 and miR- 206 in pulmonary artery smooth muscle cell (PASMC) proliferation. Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. During the last couple of years, the number of studies on the role of microRNA in PAH has broadened, defining it clearly as a HOT TOPIC. This current review presents an overview of the most recent knowledge as well as future possibilities. The use of microRNA therapies is still uncertain and poorly applied in the clinical setting yet. It is still critical to increase the knowledge and the translational potential of this HOT TOPIC to make it become a HOPE TOPIC.
Export Options
About this article
Cite this article as:
Meloche Jolyane, Paulin Roxane, Provencher Steeve and Bonnet Sebastien, Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension, Current Vascular Pharmacology 2015; 13 (3) . https://dx.doi.org/10.2174/15701611113119990010
DOI https://dx.doi.org/10.2174/15701611113119990010 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Three-phase Hollow fiber Liquid-phase Micro Extraction for Determination and Analysis of Terazosin in Biological Fluids Via High Performance Liquid Chromatography at Trace Levels
Current Analytical Chemistry Urate Transport: Regulators of Serum Urate Levels in Humans
Current Rheumatology Reviews Noninvasive Diagnosis of Chemotherapy Related Cardiotoxicity
Current Cardiology Reviews Angiotensin II Blockade and Renal Protection
Current Pharmaceutical Design Capsaicin Sensitive-Sensory Nerves and Blood Pressure Regulation
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Target Based Drug Design - A Reality in Virtual Sphere
Current Medicinal Chemistry Aldosterone and Resistant Hypertension
Current Hypertension Reviews Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Primary Vesicoureteric Reflux and Reflux Nephropathy - New Insights
Current Pediatric Reviews Ischemic Strokes in Congenital Bleeding Disorders: Comparison with Myocardial Infarction and other Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets Targets Involved in Cardioprotection by the Non-Anesthetic Noble Gas Helium
Current Drug Targets New Emerging Prospects in the Pharmacotherapy of Hypertension
Cardiovascular & Hematological Agents in Medicinal Chemistry New Developments in Anti-Platelet Therapies Potential Use of CD39/Vascular ATP Diphosphohydrolase in Thrombotic Disorders
Current Drug Targets Molecular Docking, In-Silico ADMET Study and Development of 1,6- Dihydropyrimidine Derivative as Protein Tyrosine Phosphatase Inhibitor: An Approach to Design and Develop Antidiabetic Agents
Current Computer-Aided Drug Design Interventions Against Sarcopenia in Older Persons
Current Pharmaceutical Design Biochemical Markers in the Prediction of Contrast-induced Acute Kidney Injury
Current Medicinal Chemistry Progress and Issues of the Genome-Wide Association Study for Hypertension
Current Medicinal Chemistry Editorial (Thematic Issue: Old Facts and New Perspectives to Face Alzheimer’s Dementia. Focus on Non Neuronal Participants to Neurodegeneration)
CNS & Neurological Disorders - Drug Targets Foreword:
Current Pharmaceutical Design Targeting New Pharmacological Approaches for Alzheimer’s Disease: Potential for Statins and Phosphodiesterase Inhibitors
CNS & Neurological Disorders - Drug Targets